Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emily Hayes

San Francisco, CA
Emily Hayes is a writer/editor with over 20 years’ experience in medical journalism, including magazines for specialist clinicians, government health publications, business newswires and pharma trade press.  Her educational background lies in journalism and political science. Emily has dual citizenship and has experience working in the UK and US. Since 2008, she has been a senior writer on staff with “The Pink Sheet,” working out of her home base in biopharma hub San Francisco. She enjoys covering drug development, with special areas of focus in cancer, particularly immunotherapy, and cardiology/metabolics. She covers major scientific meetings regularly, including the American Society of Clinical Oncology, and appreciates interactions with key opinion leaders while interpreting drug trial results. In her free time, she is a professional jazz/blues/country vocalist.
Advertisement
Set Alert for Articles By Emily Hayes

Latest From Emily Hayes

US FDA Fine-Tunes Tecentriq, Keytruda First-Line Bladder Cancer Accelerated Approval Indications

FDA’s decision to restrict use based on the level of PD-L1 expression shows how confirmatory trials for accelerated approval can help to inform and adapt labeling. 

Approvals Post Market Regulation & Studies

ADA Meeting's Around The Corner: Five Things To Watch For

Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.

Clinical Trials Research & Development

Daiichi's Phase III Quizartinib Data Pave Way In Niche AML Market

Showing an overall survival improvement in the especially hard to treat FLT3-ITD mutated patients is a significant achievement in AML, analysts say.

Clinical Trials Research & Development

TMB Biomarker Is A Winding Path Rather Than Straight Road

The tumor mutational burden biomarker had a much higher profile at this year's ASCO meeting, promising to help target treatment to individuals, though practical barriers remain and testing still is not ready for prime time yet.

ASCO ImmunoOncology

Specialists Rethink Lung Cancer Treatment Plans, With Eye On IO Biomarkers

Plenary speaker at this year's ASCO meeting, Leena Gandhi, envisioned a future where individual patients receive a precisely defined immunotherapy regimen.

ASCO ImmunoOncology

FDA Finally Approves Avastin In First-Line Ovarian Cancer

Genentech says it worked closely with the agency to bring the drug to women with earlier-stage disease.

Approvals Cancer
See All
Advertisement
UsernamePublicRestriction

Register